Processing

Please wait...

Settings

Settings

Goto Application

1. WO2018125716 - MORPHINAN DERIVATIVES AND USE THEREOF

Publication Number WO/2018/125716
Publication Date 05.07.2018
International Application No. PCT/US2017/067611
International Filing Date 20.12.2017
IPC
C07D 489/02 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
489Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro furan ring systems, e.g. derivatives of -morphinan of the formula:
02with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
A61K 31/485 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
485Morphinan derivatives, e.g. morphine, codeine
A61P 25/04 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
04Centrally acting analgesics, e.g. opioids
CPC
A61K 31/485
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
485Morphinan derivatives, e.g. morphine, codeine
A61P 25/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
04Centrally acting analgesics, e.g. opioids
C07B 2200/05
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
2200Indexing scheme relating to specific properties of organic compounds
05Isotopically modified compounds, e.g. labelled
C07D 471/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
02in which the condensed system contains two hetero rings
08Bridged systems
Applicants
  • PURDUE PHARMA L.P. [US]/[US]
Inventors
  • TAFESSE, Laykea
Agents
  • YANG, Weiying
Priority Data
62/441,47002.01.2017US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) MORPHINAN DERIVATIVES AND USE THEREOF
(FR) DÉRIVÉS DE MORPHINANE ET LEUR UTILISATION
Abstract
(EN)
The application is directed to compounds of formula (I): and pharmaceutically acceptable salts, radiolabeled isomers, solvates, or hydrates thereof, wherein R1, R2, R3, X, and n are defined as set forth in the specification. The application is also directed to compounds of formulae II, I-a, I-al, I-a2, I-b, and I-b1 and the pharmaceutically acceptable salts, radiolabeled isomers, solvates, and hydrates thereof. The application is also directed to use of Compounds of the present disclosure to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain Compounds of the present disclosure are especially useful for treating pain. In one embodiment, Compounds of the present disclosure exhibit less opioid-induced side effects (such as, euphoria or drug-liking).
(FR)
La présente invention concerne des composés de formule (I) : et leurs sels, isomères radiomarqués, solvates, ou hydrates pharmaceutiquement acceptables, où R1, R2, R3, X, et n sont définis tel qu’exposé dans la description. La présente invention concerne également des composés des formules (II), (I-a), (I-a1), (I-a2), (I-b), et (I-b1) et leurs sels, isomères radiomarqués, solvates, et hydrates pharmaceutiquement acceptables. L’application concerne également l’utilisation des composés de la présente invention pour traiter des troubles responsables de la modulation d’un ou plusieurs récepteurs des opioïdes, ou intermédiaires synthétiques. Certains composés de la présente invention sont spécialement utiles pour traiter la douleur. Dans un mode de réalisation, les composés de la présente invention font preuve de moins d’effets secondaires induits par les opioïdes (tels que, l’euphorie ou le fait de prendre goût au médicament).
Also published as
Latest bibliographic data on file with the International Bureau